NCT01217931 2026-01-30Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START TrialM.D. Anderson Cancer CenterPhase 2 Active not recruiting180 enrolled
NCT01392183 2021-09-20Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)M.D. Anderson Cancer CenterPhase 2 Completed69 enrolled 15 charts